Full Library
Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients
Resource type
Journal Article
Authors/contributors
- Ni, Bin (Author)
- Wolfe, Cameron R (Author)
- Arif, Sana (Author)
- Carugati, Manuela (Author)
- Heldman, Madeleine R (Author)
- Messina, Julia A (Author)
- Miller, Rachel A (Author)
- Saullo, Jennifer L (Author)
- Baker, Arthur W (Author)
- Maziarz, Eileen K (Author)
Title
Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients
Abstract
Abstract
We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.
Publication
Open Forum Infectious Diseases
Date
2024-06-28
Volume
11
Issue
7
Pages
ofae335
Accessed
7/9/24, 8:11 PM
ISSN
2328-8957
Language
en
Library Catalog
DOI.org (Crossref)
Citation
Ni, B., Wolfe, C. R., Arif, S., Carugati, M., Heldman, M. R., Messina, J. A., Miller, R. A., Saullo, J. L., Baker, A. W., & Maziarz, E. K. (2024). Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 11(7), ofae335. https://doi.org/10.1093/ofid/ofae335
Link to this record